Proteomics International has secured a contract with Dutch/Australian company BiosanaPharma to conduct an analytical comparability study on a drug treatment for allergic asthma.
The company is also pleased to announce that it nears cash flow positive position from analytical services operations, with new revenue from PromarkerD licences also expected later in 2018.
